p.144 抽出テキスト

Manage 1992;7:209‒13 9) Brema F, Pastorino G, Martini MC, et al. Oral tramadol and buprenorphine in tumour pain. An Italian multicentre trial. Int J Clin Pharmacol Res 1996;16:109‒16 10) Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system(TDS), in the treatment of patients with chronic pain. A randomised, double‒blind, placebo controlled study. The Pain Clinic 2003;15:193‒202 11) Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders:a multicenter, randomized, double‒blind, placebo‒controlled trial. Clin Ther 2003;25: 150‒68 12) Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain:results of a phase III, multicenter, randomized, double‒blind, placebo‒controlled study. Clin Ther 2004; 26:1808‒20 13)Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in long‒term control of chronic pain in cancer patients. Front Biosci 2007;12:1291‒9 14) Poulain P, Denier W, Douma J, et al. Efficacy and safety of transdermal buprenorphine:a randomized, placebo‒controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage 2008;36:117‒25 15) Wang J, Cai B, Huang DX, et al. Decreased analgesic effect of morphine, but not buprenorphine, in patients with advanced P‒glycoprotein(+)cancers. Pharmacol Rep 2012;64:870‒7 16) Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy:a

prospective comparison of oral sustained‒release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009;13:737‒43

【参考文献】a) Schmidt‒Hansen M, Bromham N, Taubert M, et al. Buprenorphine for treating cancer pain.

Cochrane Database Syst Rev 2015;3:CD009596 III章推奨